Table 4.
Effect of Baishouwu extract on the distribution of inflammatory features in the diethylnitrosamine treated rats assessed by METAVIR score.
| Time | Group | A0 | A1 | A2 | A3 | P value (vs. model) |
|---|---|---|---|---|---|---|
| Inflammation stage (6 weeks) | Control | 8 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | 0.001 |
| Model | 0 (0%) | 0 (0%) | 0 (0%) | 8 (100%) | ||
| Baishouwu-L | 0 (0%) | 3 (37.5%) | 3 (37.5%) | 2 (25.0%) | 0.001 | |
| Baishouwu-H | 0 (0%) | 4 (50.0%) | 4 (50.0%) | 0 (0%) | 0.001 | |
| Fibrosis stage (10 weeks) | Control | 8 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | 0.001 |
| Model | 0 (0%) | 0 (0%) | 0 (0%) | 8 (100%) | ||
| Baishouwu-L | 0 (0%) | 2 (25.0%) | 2 (25.0%) | 4 (50.0%) | 0.001 | |
| Baishouwu-H | 0 (0%) | 3 (37.5%) | 3 (37.5%) | 2 (25.0%) | 0.001 | |
| HCC stage (20 weeks) | Control | 8 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | 0.001 |
| Model | 0 (0%) | 0 (0%) | 0 (0%) | 8 (100%) | ||
| Baishouwu-L | 0 (0%) | 0 (0%) | 3 (37.5%) | 5 (62.5%) | 0.001 | |
| Baishouwu-H | 0 (0%) | 1 (12.5%) | 4 (50.0%) | 3 (37.5%) | 0.001 |
Compared to model group; calculated using the Chi-Square test. METRAVIR inflammation stages: A0, no activity; A1, mild activity; A2, moderate activity; A3, severe activity.